z-logo
Premium
The prognostic significance of CA 125 in patients with non‐Hodgkin's lymphoma
Author(s) -
Zacharos Ioannis D.,
Efstathiou Stamatis P.,
Petreli Elisa,
Georgiou George,
Tsioulos Dimitrios I.,
Mastorantonakis Stylianos E.,
Christakopoulou Ioulia,
Roussou Paraskevi P.
Publication year - 2002
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2002.02771.x
Subject(s) - medicine , gastroenterology , immunoradiometric assay , international prognostic index , lymphoma , stage (stratigraphy) , b symptoms , hodgkin lymphoma , radioimmunoassay , rituximab , paleontology , biology
Objective : To assess the association of serum CA 125 in patients with non‐Hodgkin's lymphoma (NHL) with prognostic parameters of the disease, response to treatment, and survival. Patients and methods : Sixty‐eight patients [38 males, median age 56 (range 17–82) yr] with NHL were evaluated. CA 125 was measured by an enzyme immunoradiometric assay at diagnosis and at the end of first‐line treatment. Results : Median overall CA 125 was 49 (1–963) U mL −1 , whereas 49 patients had initially abnormal (>35 U mL) CA 125 levels. High CA 125 was found to correlate with failure of treatment ( P  = 0.001) and relapse ( P  = 0.01), and to be independently associated with bulky disease, effusions, LDH, and the International Prognostic Index (IPI) score ( P <0.01 for each of these four variables). An initially abnormal CA 125 value was associated with poorer 5‐yr survival [median survival of patients with CA 125>35 U mL −1 33 (18–72) months compared to 58 (20–77) months for those with CA 125 = 35 U mL −1 , P  = 0.012]. Moreover, CA 125>35 U mL −1 (among stage III/IV and LDH>460 mU mL −1 ) emerged as an independent predictor of death within 5 yr from diagnosis (Relative Risk (RR) 3.1, 95% CI 1.5–12.8, P  = 0.02). Conclusion : Measurement of serum CA 125 is useful for staging, monitoring, and estimating prognosis in patients with NHL.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here